PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Poly(ADP-ribose) polymerase-1 (PARP1) inhibitors are primarily used for BRCA-deficient cancers.
• Emerging evidence suggests PARP1 inhibitors have broader applications in cancer therapy.
• The precise mechanisms underlying PARP1 inhibitor-mediated tumor suppression beyond DNA repair are not fully understood.

Purpose of the Study:

• To investigate the additional targets of PARP1 inhibitors in cancer treatment.
• To elucidate the role of AKT signaling pathway in PARP1 inhibitor efficacy.
• To explore PHLPP1 as a mediator of PARP1 inhibitor activity.

Main Methods:

• Treatment of cancer cells with PARP1 inhibitors (PJ-34 and 3-AB).
• Assessment of AKT phosphorylation at S473 and downstream targets like FOXO3A.
• Analysis of PHLPP1 expression levels and functional impact via overexpression and knockdown.

Main Results:

• PARP1 inhibitors PJ-34 and 3-AB reduced AKT phosphorylation at S473 independently of DNA repair.
• These inhibitors decreased FOXO3A phosphorylation, increased its nuclear retention, and enhanced its transcriptional activity.
• PJ-34 and 3-AB treatment significantly upregulated PHLPP1 levels, which mediated AKT inhibition and promoted tumor cell death.

Conclusions:

• PARP1 inhibitors effectively inhibit AKT signaling, offering a mechanism beyond DNA repair.
• PHLPP1 upregulation is a key mediator of PARP1 inhibitor-induced AKT inhibition and tumor cell death.
• Targeting PHLPP1 in conjunction with PARP1 inhibitors presents a novel therapeutic strategy for broader cancer treatment.